Partner Headlines - BIIB

  1. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD
  2. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga
  3. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD
  4. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD
  5. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts
  6. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  7. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD
  8. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech ...

    Benzinga
  9. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of ...

    Benzinga
  10. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study ...

    Benzinga
  11. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD
  12. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD
  13. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts
  14. Allianz's Analyst Likes Biogen, Celgene & Gilead

    Benzinga
  15. Indexes Trim Losses But Remain Lower At Midday

    IBD
  16. Biogen: Moving From Collaboration To Innovation

    IBD
  17. Economic Data Fuel Another All-Time High For S&P 500

    IBD
  18. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  19. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD
  20. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD
  21. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD
  22. Biogen's buy rating reaffirmed

    IBD
  23. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy ...

    Benzinga
  24. Perrigo Regains Some Lost Ground On Fiscal Q4 Beat

    IBD
  25. Perrigo Q4 Beats Estimates, But Guidance Misses

    IBD
  26. Tech, Health Care Lead Q2 Earnings Beats

    IBD
  27. #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes ...

    Benzinga
  28. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  29. Why Investors Should Closely Watch Celgene

    Benzinga
  30. Biotech Gets A Lift On Popular Drug, Strong Pipeline

    IBD
  31. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus
  32. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus
  33. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD
  34. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  35. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  36. Biogen, Gilead Profits Soar

    IBD
  37. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  38. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD
  39. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  40. Vertex Is Poised For An Earnings Breakout

    Benzinga
  41. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential ...

    Benzinga
  42. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD
  43. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  44. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  45. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  46. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD
  47. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga
  48. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck ...

    IBD
  49. Morning Market Movers

    Benzinga
  50. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, ...

    Benzinga
  51. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  52. Benzinga's Top #PreMarket Gainers

    Benzinga
  53. Earnings Scheduled For July 23, 2014

    Benzinga
  54. Stocks Rise; Apple, Microsoft Steady In Post-Session

    IBD
  55. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  56. Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out

    IBD
  57. Oil Dominates; Keurig, Constellation Near Buy Points

    IBD
  58. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  59. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  60. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  61. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  62. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  63. Baxter Q2 Earnings Beat Estimates, But Guidance Soft

    IBD
  64. IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market

    IBD
  65. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
  66. Stocks Close Higher As Biotech, Internet Stocks Gain

    IBD
  67. Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds ...

    Benzinga
  68. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  69. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  70. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  71. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  72. AbbVie, Shire Give Bullish Guidance Amid Buyout Talk

    IBD
  73. ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart ...

    Benzinga
  74. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  75. Biogen, AbbVie Report Positive Top-Line Results from Phase 3 ...

    Benzinga
  76. 50-Day Moving Average Can Buffer A Strong Stock's Advance

    IBD
  77. UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive ...

    Benzinga
  78. Stock Indexes Slightly Up; Apple Split Takes Effect

    IBD
  79. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Good ...

    Benzinga
  80. US Stock Futures Slightly Lower Ahead Of McDonald's Sales Report

    Benzinga
  81. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  82. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  83. Investor's Corner: How To Use The Big Cap 20

    IBD
  84. Walgreen Shares Climb Sharply in Holiday-Lifted April

    IBD
  85. Walgreen Hits Record Close On Sweet Easter Sales

    IBD
  86. Biogen to Present Plegridy Data from Phase 3 Study at AAN Annual ...

    Benzinga
  87. Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile ...

    Benzinga
  88. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  89. Market Wrap For April 24: Apple's Smashing Earnings Overshadowed ...

    Benzinga
  90. Biogen EPS misses, guides up

    IBD
  91. Biogen Q1, Guidance Strong, But Stock Slips

    IBD
  92. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  93. Biogen Q1 Sales Beat Street, Guidance Strong

    IBD
  94. Earnings Scheduled For April 23, 2014

    Benzinga
  95. Ken Fisher's Top Increases of the First Quarter

    GuruFocus
  96. A Drill Can Help Identify Right Time To Sell Leaders

    IBD
  97. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  98. Johnson & Johnson: Why Top Funds Are Buying

    YCharts
  99. Biogen Idec Signs License Agreement With Amunix for XTENylated ...

    Benzinga
  100. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
Trading Center